- Patients with COVID-19 and active cancer have an increased risk for 30-day all-cause mortality.
- Independent risk factors for mortality in patients with COVID-19 and cancer include older age, male sex, former smoking, number of comorbidities, and Eastern Cooperative Oncology Group (ECOG) performance status ≥2.
Why this matters
- Patients with cancer are typically older individuals with comorbidities, and their immune systems may be compromised as a result of cancer and/or chemotherapy.
- Analysis of 928 patients (median age, 66 years) from the COVID-19 and Cancer Consortium (CCC19) registry.
- Funding: NIH; American Cancer Society.
- Overall, 39% of patients were receiving active cancer treatment, and 43% had measurable disease.
- 121 patients (13%) had died at a median follow-up of 21 days.
- All deaths occurred within 30 days of COVID-19 diagnosis.
- Of those who died:
- 78 were male;
- 64 were former smokers;
- 70 were age ≥75 years;
- 41 had active stable or responsive cancer;
- 25 had progressing cancer; and
- 42 had an ECOG performance status ≥2.
- Of the patients hospitalized, 23% died:
- Of those admitted to an ICU, 38% died;
- Of those who required intubation, 43% died.
- Small sample size and short follow-up.
- ASCO President Howard A. Burris III, MD, said: "For people with cancer, the impact of COVID-19 is especially severe, whether they have been exposed to the virus or not."